Alexander Slade is an Oncology physician affiliated with Stony Brook School. OpenAlex indexes 59 publications with 338 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20251 payment
- Boston Scientific CorporationProgram year20251 payment
- Blue Earth Diagnostics LimitedProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
66.8%alpha-Adrenergic Blocker66.8%Tamsulosin Hcl100%Part D≥51 patientsCancer & immunology
21.8%Androgen Receptor Inhibitor12.8%Bicalutamide100%Part D≥25 patientsGonadotropin Releasing Hormone Receptor Antagonist9%Orgovyx100%Part D<11 patientsSensory organs
6.2%Fluoroquinolone Antibacterial6.2%Ciprofloxacin Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Primary Endpoint Analysis of a Multi-Center Phase II Randomized Control Trial of Neurovascular-Sparing SAbR in Localized Prostate Cancer (Late Breaking Abstract)
International Journal of Radiation Oncology*Biology*Physics
2026 - Genitourinary Dosimetry and Early Urinary Quality of Life in a Randomized Prostate SAbR Trial with Planned Dose Heterogeneity
International Journal of Radiation Oncology*Biology*Physics
2026 - A Randomized, Prospective Trial of Hydrogen-Rich Water (HRW) to Mitigate Acute Mucositis during Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gabrielle Carlson, MD
Stony Brook School
Anne Ambrose, MD
Stony Brook School
Sandeep Mallipattu
Stony Brook School
Roberta Seidman, MD
Stony Brook School
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”